Stockpolly
Search
BNTC · NASDAQ · Biotechnology

Benitec Biopharma (BNTC)

Develops BB-301, a ddRNAi genetic medicine for OPMD dysphagia.

$12.88
At close+0.57 (+4.63%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Jun 2023Q1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026
Revenue000000001000
Cost of revenue000000000000
Gross profit000000000000
567466111517101313
Research & development345344564366
1222225913687
General & administrative1222225913687
Other expenses000000000000
Operating income−5−6−7−4−6−6−11−15−17−10−13−14
000011111122
Interest income000010110002
Interest expense00000−100−1−1−10
Other non-operating income000000000000
Income before tax−5−6−7−4−5−5−10−15−16−9−12−12
Net income from continuing operations−5−6−7−4−5−5−10−15−16−9−12−12
Net income−5−6−7−4−5−5−10−15−16−9−12−12
EPS, basic−$1.41−$0.60−$0.54−$0.23−$0.53−$0.48−$0.33−$0.38−$0.39−$0.22−$0.26−$0.24
EPS, diluted−$1.41−$0.60−$0.54−$0.23−$0.53−$0.48−$0.33−$0.38−$0.39−$0.22−$0.26−$0.24
Weighted average shares, basic7910101011223936424649
Weighted average shares, diluted7910101011223936424649
EBITDA−5−6−7−4−5−6−11−15−17−10−13−13
Depreciation & amortization000000000000
EBIT−5−6−7−4−5−6−11−15−17−10−13−14